Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NYSE:NIO NYSE:TWLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$58.54+4.4%$49.63$30.04▼$71.13$5.08B1.82.57 million shs1.17 million shsNIONIO$4.63-7.7%$3.88$3.02▼$7.71$9.63B1.4151.34 million shs51.46 million shsTWLOTwilio$124.67+2.9%$121.57$56.85▼$151.95$19.02B1.232.84 million shs811,842 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%-13.39%+7.54%+49.10%+9.74%NIONIO0.00%+1.73%+43.35%+26.04%+23.70%TWLOTwilio0.00%-7.52%+0.61%+17.51%+92.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics2.8207 of 5 stars3.32.00.00.03.03.30.6NIONIO0.6333 of 5 stars1.12.00.00.02.40.80.6TWLOTwilio4.0977 of 5 stars2.33.00.03.13.52.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$70.0719.69% UpsideNIONIO 2.23Hold$4.742.55% UpsideTWLOTwilio 2.68Moderate Buy$127.222.04% UpsideCurrent Analyst Ratings BreakdownLatest NIO, TWLO, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025CRSPCRISPR TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$79.00 ➝ $78.007/14/2025NIONIOMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/14/2025TWLOTwilioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$121.00 ➝ $140.007/8/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.006/17/2025NIONIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$3.70 ➝ $3.806/15/2025TWLOTwilioJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ Hold$132.00(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M135.50N/AN/A$22.64 per share2.59NIONIO$67.86B0.14N/AN/A$0.40 per share11.56TWLOTwilio$4.46B4.27$2.53 per share49.37$52.11 per share2.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)NIONIO-$3.06B-$1.62N/AN/AN/A-35.51%-286.45%-23.51%9/4/2025 (Estimated)TWLOTwilio-$109.40M-$0.21N/A53.973.66-0.74%2.25%1.84%8/7/2025 (Confirmed)Latest NIO, TWLO, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025TWLOTwilio$1.02N/AN/AN/A$1.19 billionN/A8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.54N/AN/AN/A$6.44 millionN/A6/3/2025Q1 2025NIONIO-$0.22-$0.45-$0.23-$0.45$12.46 billion$1.66 billion5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANIONION/AN/AN/AN/AN/ATWLOTwilioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A15.6415.64NIONIO1.890.840.69TWLOTwilio0.124.784.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%NIONIO48.55%TWLOTwilio84.27%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%NIONIO1.00%TWLOTwilio4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46086.36 million82.82 millionOptionableNIONIO45,6352.09 billion2.07 billionOptionableTWLOTwilio5,535152.67 million145.80 millionOptionableNIO, TWLO, and CRSP HeadlinesRecent News About These CompaniesTwilio Set to Report Q2 Earnings: What's in Store for the Stock?1 hour ago | zacks.comSeeking Clues to Twilio (TWLO) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics2 hours ago | zacks.comJ. Safra Sarasin Holding AG Has $2.59 Million Stock Holdings in Twilio Inc. (NYSE:TWLO)August 4 at 7:04 AM | marketbeat.comJupiter Asset Management Ltd. Has $19.23 Million Stock Position in Twilio Inc. (NYSE:TWLO)August 4 at 6:43 AM | marketbeat.comTwilio, Google Power Fresha Boosts Customer Engagement with RCS MessagingAugust 3 at 12:09 AM | thefastmode.comTEmpirical Financial Services LLC d.b.a. Empirical Wealth Management Sells 2,222 Shares of Twilio Inc. (NYSE:TWLO)August 3 at 7:35 AM | marketbeat.comBanque Cantonale Vaudoise Takes Position in Twilio Inc. (NYSE:TWLO)August 3 at 7:22 AM | marketbeat.comCetera Investment Advisers Decreases Stake in Twilio Inc. (NYSE:TWLO)August 3 at 4:07 AM | marketbeat.comTwilio Inc. (NYSE:TWLO) Sees Significant Growth in Short InterestAugust 2 at 4:31 PM | marketbeat.comAE Wealth Management LLC Buys New Shares in Twilio Inc. (NYSE:TWLO)August 2 at 6:41 AM | marketbeat.comMenard Financial Group LLC Purchases Shares of 3,203 Twilio Inc. (NYSE:TWLO)August 1 at 8:36 AM | marketbeat.comBayforest Capital Ltd Increases Stake in Twilio Inc. (NYSE:TWLO)August 1 at 7:50 AM | marketbeat.comTwilio Inc. (TWLO) Rated as ‘Market Perform’ at JMP SecuritiesJuly 31, 2025 | msn.comTwilio (TWLO) Reports Next Week: Wall Street Expects Earnings GrowthJuly 31, 2025 | zacks.comTwilio Inc. (TWLO) is Attracting Investor Attention: Here is What You Should KnowJuly 31, 2025 | zacks.comTwilio Inc. (NYSE:TWLO) Holdings Increased by Zurcher Kantonalbank Zurich CantonalbankJuly 31, 2025 | marketbeat.comTwilio (TWLO) Expected to Announce Earnings on ThursdayJuly 31, 2025 | marketbeat.comTwilio (TWLO) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJuly 29, 2025 | zacks.comValliance Asset Management Ltd Makes New Investment in Twilio Inc. (NYSE:TWLO)July 29, 2025 | marketbeat.comTwilio Inc. (NYSE:TWLO) Position Trimmed by Mediolanum International Funds LtdJuly 29, 2025 | marketbeat.comVictory Capital Management Inc. Buys 5,399 Shares of Twilio Inc. (NYSE:TWLO)July 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNIO, TWLO, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$58.54 +2.45 (+4.36%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.NIO NYSE:NIO$4.62 -0.39 (-7.68%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NIO Inc. designs, manufactures, and sells electric vehicles in the People's Republic of China. The company is also involved in the manufacture of e-powertrain, battery packs, and components; and racing management, technology development, and sales and after-sales management activities. In addition, it offers power solutions for battery charging needs; and other value-added services. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Twilio NYSE:TWLO$124.67 +3.51 (+2.90%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Twilio Inc., together with its subsidiaries, provides customer engagement platform solutions in the United States and internationally. It operates through two segments, Twilio Communications and Twilio Segment. The company provides various application programming interfaces and software solutions for communications between customers and end users, including messaging, voice, email, flex, marketing campaigns, and user identity and authentication. It also offers software products to build direct, personalized relationships with their end users, such as segment, a platform that provides tools for first-party data by unifying real-time information collected; and engage, an automation platform for the delivery of omnichannel campaigns. Twilio Inc. was incorporated in 2008 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
